We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Haemonetics Strong on Plasma & Hemostasis Management Units
Read MoreHide Full Article
On Nov 14, we issued an updated research report on Haemonetics Corporation (HAE - Free Report) . The company has been witnessing strong growth in Plasma and Hemostasis Management units for quite some time now. The stock currently carries a Zacks Rank #2 (Buy).
Shares of this leading provider of hematology products and solutions have outperformed its industry over the past year. The stock has gained 89.7% compared with the industry’s 1.2% rally.
Haemonetics’ Plasma arm continued to witness strong growth in the fiscal second quarter on a 13.3% rise in revenues at constant currency. In the quarter, North America Plasma revenues increased double-digits led by strength in disposables along with growing software revenues.
Haemonetics also continues to make investments to expand disposable capacity. During the reported quarter, the company finished validation of its new bottle line. Per management, the company is on track to complete and validate its new bowl line by the end of the fiscal 2019. Together, all of these are expected to raise Haemonetics’ disposable capacity by 50%.
We are also upbeat about Haemonetcs’ Hemostasis Management business which has been seeing strong growth in the past few quarters. Also, TEG has become the global leader in Hemostasis Management led by solid disposable growth and amplified TEG success capital sales. Double-digit sales growth in both TEG 5000 and TEG 6s disposables also encourages us.
The company’s launch of a product line extension, namely, TEG Manager 4.0, a software solution embedded with a new feature called the interpretation guidance module is also impressive.
Moreover, the fiscal 2019 guidance looks promising. In addition, the company’s strong cash position boosts investors’ confidence.
Other Key Picks
Other top-ranked stocks in the broader medical space are Stryker Corporation (SYK - Free Report) , Masimo Corporation (MASI - Free Report) and Veeva Systems (VEEV - Free Report) .
Masimo’s long-term earnings growth rate is projected at 14.6%. The stock carries a Zacks Rank #2.
Veeva Systems’ long-term earnings growth rate is estimated at 19.3%. The stock carries a Zacks Rank #2.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Image: Bigstock
Haemonetics Strong on Plasma & Hemostasis Management Units
On Nov 14, we issued an updated research report on Haemonetics Corporation (HAE - Free Report) . The company has been witnessing strong growth in Plasma and Hemostasis Management units for quite some time now. The stock currently carries a Zacks Rank #2 (Buy).
Shares of this leading provider of hematology products and solutions have outperformed its industry over the past year. The stock has gained 89.7% compared with the industry’s 1.2% rally.
Haemonetics’ Plasma arm continued to witness strong growth in the fiscal second quarter on a 13.3% rise in revenues at constant currency. In the quarter, North America Plasma revenues increased double-digits led by strength in disposables along with growing software revenues.
Haemonetics also continues to make investments to expand disposable capacity. During the reported quarter, the company finished validation of its new bottle line. Per management, the company is on track to complete and validate its new bowl line by the end of the fiscal 2019. Together, all of these are expected to raise Haemonetics’ disposable capacity by 50%.
We are also upbeat about Haemonetcs’ Hemostasis Management business which has been seeing strong growth in the past few quarters. Also, TEG has become the global leader in Hemostasis Management led by solid disposable growth and amplified TEG success capital sales. Double-digit sales growth in both TEG 5000 and TEG 6s disposables also encourages us.
The company’s launch of a product line extension, namely, TEG Manager 4.0, a software solution embedded with a new feature called the interpretation guidance module is also impressive.
Moreover, the fiscal 2019 guidance looks promising. In addition, the company’s strong cash position boosts investors’ confidence.
Other Key Picks
Other top-ranked stocks in the broader medical space are Stryker Corporation (SYK - Free Report) , Masimo Corporation (MASI - Free Report) and Veeva Systems (VEEV - Free Report) .
Stryker has a long-term expected earnings growth rate of 10% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Masimo’s long-term earnings growth rate is projected at 14.6%. The stock carries a Zacks Rank #2.
Veeva Systems’ long-term earnings growth rate is estimated at 19.3%. The stock carries a Zacks Rank #2.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>